Paper Details

  1. Home
  2. Paper Details

Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered<sup>&#174;</sup> Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.

Author: HalkerRashmi, MahmoudRamy A, McAllisterPeter J, SiffertJoao, SilbersteinStephen, TepperStewart J, WinnerPaul K

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Label='OBJECTIVE' NlmCategory='OBJECTIVE'>To further characterize the clinical utility of AVP-825 based on additional prespecified outcomes and post hoc analyses of COMPASS, a Phase 3 comparative efficacy trial of AVP-825 vs 100 mg oral sumatriptan (NCT01667679). AVP-825 was approved in January 2016 by the US Food and Drug Administration under the name ONZETRA<sup>&#174;</sup> Xsail<sup>&#174;</sup> (sumatriptan nasal powder) for the acute treatment of migraine with or without aura in adults.
Paper Details　
Original Abstract of the Article :
Label="OBJECTIVE" NlmCategory="OBJECTIVE">To further characterize the clinical utility of AVP-825 based on additional prespecified outcomes and post hoc analyses of COMPASS, a Phase 3 comparative efficacy trial of AVP-825 vs 100 mg oral sumatriptan (NCT01667679). AVP-825 was approved in January 2016...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/head.13105

データ提供：米国国立医学図書館（NLM）

AVP-825: A Breath of Fresh Air for Migraine Sufferers?

Migraine, a debilitating condition characterized by severe headaches, affects millions of people worldwide. This study, like a determined explorer seeking a cure for a mysterious ailment, investigates the effectiveness of AVP-825, a novel nasal powder formulation of sumatriptan, for the acute treatment of migraine. The research, conducted as a Phase 3 comparative efficacy trial, compares AVP-825 to oral sumatriptan, exploring its efficacy and consistency of response across multiple migraine attacks.

A New Frontier in Migraine Treatment: AVP-825 Shows Promise

The study found that AVP-825 demonstrated promising efficacy in the acute treatment of migraine, with a rapid onset of action and consistent relief across multiple migraine attacks. This new approach to migraine treatment offers a potential alternative for those who may not achieve satisfactory relief with oral medications.

Embracing Innovation: Expanding Treatment Options for Migraine

This research highlights the importance of continuous innovation in the development of new and effective treatments for migraine. The study's findings suggest that AVP-825 may offer a valuable addition to the existing armamentarium of migraine therapies, providing patients with a broader range of options to manage their condition effectively.

Dr.Camel's Conclusion

This study is a reminder that the pursuit of effective migraine treatments is an ongoing journey. By embracing innovation and exploring new therapeutic approaches, researchers are bringing us closer to a world where migraine sufferers can experience relief and live fulfilling lives.

Date :
  1. Date Completed 2018-03-21
  2. Date Revised 2018-03-21
Further Info :

Pubmed ID

28497569

DOI: Digital Object Identifier

10.1111/head.13105

Related Literature

Article Analysis
・Effects of sumatriptan nasal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.